NCT06135415 2026-03-25
TirbAKare
Almirall, S.A.
Phase 3 Completed
Clinical Trials
12 trialsNCT07273656 2025-12-09
TIRBACRYO
University Hospital, Lille
Phase 3 Not yet recruiting
NCT05741294 2025-02-20
A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses
Almirall, S.A.
Phase 4 Completed
NCT05387525 2025-02-11
AKtive
Almirall, S.A.
Phase 4 Active not recruiting
NCT05260073 2024-09-20
PROAK
Almirall, S.A.
Completed
NCT06026358 2024-05-30
Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands
Medical University of Graz
Phase 4 Withdrawn
NCT05900258 2023-11-14
SunDamage
Medical University of Graz
Phase 4 Completed
NCT01074138 2023-02-02
Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer
Athenex, Inc.
Phase 2 Completed
NCT01397799 2015-12-07
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
Athenex, Inc.
Phase 1 Completed
NCT01764087 2015-05-18
A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1/2 Unknown
NCT00658970 2011-06-08
Evaluation of KX2-391 in Patients With Advanced Malignancies
Athenex, Inc.
Phase 1 Completed
NCT00646139 2011-03-02
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
Roswell Park Cancer Institute
Phase 1 Completed